Metformin in Type 2 Diabetes: Evidence for its Beneficial Effects on Frailty and Sarcopenia


Cite item

Full Text

Abstract

This narrative review aimed to discuss the potential interplay among frailty syndrome, sarcopenia and metformin in type 2 diabetes mellitus (T2DM). There is emerging evidence on the potential protective role of metformin on both frailty and sarcopenia. However, results are not always consistent. Thus, further research is needed to provide a definitive answer on any role of metformin in improving frailty and/or sarcopenia in T2DM.

About the authors

Elisavet Pyrgioti

Pharmacist, Private Practice, Athens, Greece

Email: info@benthamscience.net

Nikolaos Karakousis

Second Department of Internal Medicine, Diabetes Centre-Diabetic
Foot Clinic, Democritus University of Thrace, Alexandroupolis, Greece

Email: info@benthamscience.net

Petros Georgakopoulos

Primary Healthcare, Internal Medicine
Department, Amarousion, Attica, Greece

Email: info@benthamscience.net

Nikolaos Papanas

Second Department of Internal Medicine, Diabetes Centre-Diabetic
Foot Clinic, Democritus University of Thrace, Alexandroupolis, Greece

Author for correspondence.
Email: info@benthamscience.net

Supplementary files

Supplementary Files
Action
1. JATS XML
Download